# SLN

## Overview
The SLN gene encodes sarcolipin, a small regulatory peptide that plays a significant role in muscle physiology by modulating the activity of the sarco-endoplasmic reticulum Ca2+-ATPases (SERCAs). Sarcolipin is a transmembrane protein that interacts with SERCA to regulate calcium homeostasis, muscle relaxation, and thermogenesis. It is predominantly expressed in skeletal muscle, particularly in fast-twitch fibers, and is involved in energy metabolism and thermogenic processes. The protein's ability to uncouple SERCA activity results in increased ATP hydrolysis and heat production, which is crucial for maintaining body temperature and energy balance. Sarcolipin's interaction with SERCA is essential for its regulatory functions, and alterations in its expression have been linked to various muscle and cardiac conditions, highlighting its clinical significance (Mareedu2019Sarcolipin; Barbot2015Functional).

## Structure
Sarcolipin (SLN) is a 31-amino acid membrane protein that forms a single transmembrane alpha-helix. The primary structure of SLN includes a hydrophilic N-terminal domain of 7 amino acids, a hydrophobic transmembrane helical domain of 19 amino acids, and a hydrophilic C-terminal domain of 5 amino acids (Odermatt1997Characterization). The secondary structure of SLN is characterized by an α-helical conformation extending from residue Phe-9 to Arg-27, with unstructured regions at both the N-terminus (M1-L8) and C-terminus (S28-Y31) (Traaseth2007Structural). 

In terms of tertiary structure, SLN interacts with the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA1a) within a groove between the M2, M6, and M9 transmembrane helices, forming a slightly bent membrane-spanning helix (Barbot2015Functional). The quaternary structure involves SLN forming a 1:1 heterodimeric complex with SERCA, which is crucial for its regulatory function (Autry2016Sarcolipin). 

SLN undergoes post-translational modifications, including acylation at Cys9 with either palmitic or oleic acid, which is essential for its full inhibitory effect on SERCA1a (Barbot2015Functional). This modification distinguishes SLN from phospholamban (PLN), another SERCA regulator, which does not undergo similar acylation (Barbot2015Functional).

## Function
Sarcolipin (SLN) is a regulatory peptide that plays a crucial role in modulating the activity of the sarco-endoplasmic reticulum Ca2+-ATPases (SERCAs) in human skeletal muscle cells. SLN inhibits SERCA by decreasing its calcium transport rate, which affects muscle relaxation and thermogenesis. This inhibition is achieved by reducing the calcium affinity of SERCA and altering its conformational states, favoring a low-affinity E2-like state (Barbot2021Deciphering; Barbot2015Functional).

SLN is highly expressed in human skeletal muscle, particularly in fast-twitch fibers, and is involved in regulating substrate utilization and energy metabolism. It enhances fatty acid metabolism and glycolytic capacity, contributing to improved muscle energetics and reduced fatigue (Sopariwala2015Sarcolipin; Mengeste2022Knockdown). SLN's role in thermogenesis is significant, as it uncouples SERCA activity, leading to increased ATP hydrolysis and heat production, which is crucial for maintaining body temperature and energy balance (Barbot2015Functional).

In human cells, SLN's expression and function are regulated at multiple levels, including transcription and posttranslational modifications. Its interaction with SERCA is essential for maintaining calcium homeostasis and efficient muscle function (Fajardo2013CoExpression; Barbot2015Functional).

## Clinical Significance
Alterations in the expression of the sarcolipin (SLN) gene have been implicated in various muscle and cardiac conditions. In Duchenne Muscular Dystrophy (DMD), SLN is abnormally upregulated in both skeletal and cardiac muscles, which inhibits SERCA function and leads to cytosolic Ca2+ overload. This overload can activate Ca2+-dependent proteases, impair muscle regeneration, and cause mitochondrial dysfunction, muscle weakness, and cardiomyopathy. Reducing SLN expression in DMD models has shown improvements in muscle and cardiac function, suggesting that SLN upregulation is a detrimental factor in this disease (Mareedu2019Sarcolipin).

In cardiac physiology, SLN interacts with SERCA2a and phospholamban (PLB), affecting calcium homeostasis. Overexpression of SLN in the heart can lead to impaired cardiac function, including reduced contractility and ventricular hypertrophy. This is due to SLN's ability to decrease the apparent affinity of SERCA2a for Ca2+, which can be partially reversed by β-adrenergic stimulation (Asahi2004Cardiacspecific). Mutations in SLN, such as the threonine 5 to alanine mutation, can exacerbate cardiac dysfunction by constitutively inhibiting SERCA, leading to structural remodeling and diastolic dysfunction (Shanmugam2015Cardiac).

## Interactions
Sarcolipin (SLN) interacts primarily with the sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA), modulating its activity. SLN binds to SERCA even at high Ca2+ concentrations, unlike phospholamban (PLB), which does not bind at elevated Ca2+ levels. This binding promotes uncoupling of the SERCA pump by decreasing the Vmax of Ca2+ uptake without affecting ATP hydrolysis, allowing ATP hydrolysis to continue while less Ca2+ is transported to the lumen (Sahoo2013Sarcolipin). SLN and PLB may bind to the same groove on SERCA, but SLN has a higher affinity and interacts with different phosphointermediates during the kinetic cycle (Sahoo2013Sarcolipin).

SLN also forms complexes with SERCA1a, either alone or in association with PLB. The presence of SLN can increase the concentration of monomeric PLB, leading to superinhibition of SERCA through increased affinity of the PLB/SLN binary complex for SERCA (Asahi2003Sarcolipin). SLN's unique luminal C-terminal tail sequence, 27 RSYQY 31, is crucial for its function and enhances PLB's activity when added to it (Barbot2021Deciphering). SLN remains bound to SERCA1a throughout the pump cycle, even when Ca2+ binds to the sites, stabilizing the SERCA1a-SLN complex in the membrane (Barbot2021Deciphering).


## References


[1. (Asahi2004Cardiacspecific) Michio Asahi, Kinya Otsu, Hiroyuki Nakayama, Shungo Hikoso, Toshihiro Takeda, Anthony O. Gramolini, Maria G. Trivieri, Gavin Y. Oudit, Takashi Morita, Yoichiro Kusakari, Shuta Hirano, Kenichi Hongo, Shinichi Hirotani, Osamu Yamaguchi, Alan Peterson, Peter H. Backx, Satoshi Kurihara, Masatsugu Hori, and David H. MacLennan. Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum ca 2+ atpase (serca2a) activity and impairs cardiac function in mice. Proceedings of the National Academy of Sciences, 101(25):9199–9204, June 2004. URL: http://dx.doi.org/10.1073/pnas.0402596101, doi:10.1073/pnas.0402596101. This article has 94 citations.](https://doi.org/10.1073/pnas.0402596101)

[2. (Sahoo2013Sarcolipin) Sanjaya K. Sahoo, Sana A. Shaikh, Danesh H. Sopariwala, Naresh C. Bal, and Muthu Periasamy. Sarcolipin protein interaction with sarco(endo)plasmic reticulum ca2+atpase (serca) is distinct from phospholamban protein, and only sarcolipin can promote uncoupling of the serca pump. Journal of Biological Chemistry, 288(10):6881–6889, March 2013. URL: http://dx.doi.org/10.1074/jbc.m112.436915, doi:10.1074/jbc.m112.436915. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m112.436915)

[3. (Autry2016Sarcolipin) Joseph M. Autry, David D. Thomas, and L. Michel Espinoza-Fonseca. Sarcolipin promotes uncoupling of the serca ca2+ pump by inducing a structural rearrangement in the energy-transduction domain. Biochemistry, 55(44):6083–6086, October 2016. URL: http://dx.doi.org/10.1021/acs.biochem.6b00728, doi:10.1021/acs.biochem.6b00728. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/acs.biochem.6b00728)

[4. (Fajardo2013CoExpression) Val A. Fajardo, Eric Bombardier, Chris Vigna, Tahira Devji, Darin Bloemberg, Daniel Gamu, Anthony O. Gramolini, Joe Quadrilatero, and A. Russell Tupling. Co-expression of serca isoforms, phospholamban and sarcolipin in human skeletal muscle fibers. PLoS ONE, 8(12):e84304, December 2013. URL: http://dx.doi.org/10.1371/journal.pone.0084304, doi:10.1371/journal.pone.0084304. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0084304)

[5. (Asahi2003Sarcolipin) Michio Asahi, Yuji Sugita, Kazimierz Kurzydlowski, Stella De Leon, Michihiko Tada, Chikashi Toyoshima, and David H. MacLennan. Sarcolipin regulates sarco(endo)plasmic reticulum ca 2+ -atpase (serca) by binding to transmembrane helices alone or in association with phospholamban. Proceedings of the National Academy of Sciences, 100(9):5040–5045, April 2003. URL: http://dx.doi.org/10.1073/pnas.0330962100, doi:10.1073/pnas.0330962100. This article has 131 citations.](https://doi.org/10.1073/pnas.0330962100)

[6. (Traaseth2007Structural) Nathaniel J. Traaseth, Kim N. Ha, Raffaello Verardi, Lei Shi, Jarrod J. Buffy, Larry R. Masterson, and Gianluigi Veglia. Structural and dynamic basis of phospholamban and sarcolipin inhibition of ca2+-atpase. Biochemistry, 47(1):3–13, December 2007. URL: http://dx.doi.org/10.1021/bi701668v, doi:10.1021/bi701668v. This article has 115 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi701668v)

[7. (Barbot2021Deciphering) Thomas Barbot, Veronica Beswick, Cédric Montigny, Éric Quiniou, Nadège Jamin, and Liliane Mouawad. Deciphering the mechanism of inhibition of serca1a by sarcolipin using molecular simulations. Frontiers in Molecular Biosciences, February 2021. URL: http://dx.doi.org/10.3389/fmolb.2020.606254, doi:10.3389/fmolb.2020.606254. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2020.606254)

[8. (Barbot2015Functional) Thomas Barbot, Cédric Montigny, Paulette Decottignies, Marc le Maire, Christine Jaxel, Nadège Jamin, and Veronica Beswick. Functional and Structural Insights into Sarcolipin, a Regulator of the Sarco-Endoplasmic Reticulum Ca2+-ATPases, pages 153–186. Springer International Publishing, December 2015. URL: http://dx.doi.org/10.1007/978-3-319-24780-9_10, doi:10.1007/978-3-319-24780-9_10. This article has 6 citations.](https://doi.org/10.1007/978-3-319-24780-9_10)

[9. (Mareedu2019Sarcolipin) Satvik Mareedu, Shalini Dwivedi, Nandita Niranjan, and Gopal J. Babu. Sarcolipin Knockdown Therapy for Duchenne Muscular Dystrophy, pages 405–415. Springer International Publishing, 2019. URL: http://dx.doi.org/10.1007/978-3-030-03095-7_23, doi:10.1007/978-3-030-03095-7_23. This article has 2 citations.](https://doi.org/10.1007/978-3-030-03095-7_23)

[10. (Odermatt1997Characterization) Alex Odermatt, Peter E.M. Taschner, Stephen W. Scherer, Barbara Beatty, Vijay K. Khanna, David R. Cornblath, Vinay Chaudhry, Won-Chee Yee, Bertold Schrank, George Karpati, Martijn H. Breuning, Nine Knoers, and David H. Maclennan. Characterization of the gene encoding human sarcolipin (sln), a proteolipid associated with serca1: absence of structural mutations in five patients with brody disease. Genomics, 45(3):541–553, November 1997. URL: http://dx.doi.org/10.1006/GENO.1997.4967, doi:10.1006/geno.1997.4967. This article has 194 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/GENO.1997.4967)

[11. (Sopariwala2015Sarcolipin) Danesh H. Sopariwala, Meghna Pant, Sana A. Shaikh, Sanjeewa A. Goonasekera, Jeffery D. Molkentin, Noah Weisleder, Jianjie Ma, Zui Pan, and Muthu Periasamy. Sarcolipin overexpression improves muscle energetics and reduces fatigue. Journal of Applied Physiology, 118(8):1050–1058, April 2015. URL: http://dx.doi.org/10.1152/japplphysiol.01066.2014, doi:10.1152/japplphysiol.01066.2014. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1152/japplphysiol.01066.2014)

[12. (Mengeste2022Knockdown) Abel M. Mengeste, Parmeshwar Katare, Andrea Dalmao Fernandez, Jenny Lund, Hege G. Bakke, David Baker, Stefano Bartesaghi, Xiao-Rong Peng, Arild C. Rustan, G. Hege Thoresen, and Eili Tranheim Kase. Knockdown of sarcolipin (sln) impairs substrate utilization in human skeletal muscle cells. Molecular Biology Reports, 49(7):6005–6017, April 2022. URL: http://dx.doi.org/10.1007/s11033-022-07387-0, doi:10.1007/s11033-022-07387-0. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11033-022-07387-0)

[13. (Shanmugam2015Cardiac) Mayilvahanan Shanmugam, Dan Li, Shumin Gao, Nadezhda Fefelova, Vikas Shah, Antanina Voit, Ronald Pachon, Ghassan Yehia, Lai-Hua Xie, and Gopal J. Babu. Cardiac specific expression of threonine 5 to alanine mutant sarcolipin results in structural remodeling and diastolic dysfunction. PLOS ONE, 10(2):e0115822, February 2015. URL: http://dx.doi.org/10.1371/journal.pone.0115822, doi:10.1371/journal.pone.0115822. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0115822)